|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||54.17 - 54.57|
|52 Week Range||53.63 - 66.80|
|PE Ratio (TTM)||29.44|
|Earnings Date||Feb 2, 2018|
|Forward Dividend & Yield||1.88 (3.41%)|
|1y Target Est||65.43|
The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced manufacturing and R&D facilities. Though their businesses are recession-proof, a huge portion of their expenses has to be allocated to research and development to stay ahead of the competition. Medicine has […]
UPS has acquired a manufacturing pharmacy license from Georgia, enabling the shipper to repackage and relabel drugs directly from the manufacturers.
Quartet Medicine, which struck a 2015 deal with Merck & Co. worth more than $575 million, is winding down after discovering that a pain treatment it was developing posed unexpected safety risks in preclinical ...
"With earnings season now out of the way, macro news and the prospects of tax reform will basically guide the market," said Peter Cardillo, chief market economist at First Standard Financial in New York. The U.S. House of Representatives passed their version of a tax bill last week. At 9:39 a.m. ET (1339 GMT), the Dow Jones Industrial Average was up 30.76 points, or 0.13 percent, at 23,389, the S&P 500 was up 1.67 points, or 0.06 percent, at 2,580.52 and the Nasdaq Composite was up 9.19 points, or 0.14 percent, at 6,791.98.
Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial. It is a significant milestone for physicians, patients and investors, who are trying to assess the competitive landscape as drugmakers race to develop better ways to fight tumours in previously untreated lung cancer.
Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism. News that Roche's immune system-boosting drug Tecentriq delayed lung cancer progression when given alongside chemo and its older drug Avastin validates the approach for the first time in a large Phase III clinical trial.
Merck & Co., Inc. (NYSE:MRK) did not finish last week well. MRK stock hit its 52-week low on the news. As I’ve said many times before, this is when contrarian investors need to take a deeper dive and see if a great long-term company like Merck stock has been oversold, or whether it’s being justly punished for its shortcomings.
Cancer immunotherapies and targeted therapies offer renewed hope to lung-cancer patients.
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Merck & Co., Inc. Here are 5 ETFs with the largest exposure to MRK-US. Comparing the performance and risk of Merck & Co., Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Merck & Co., Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Merck & Co., Inc. – Pfizer Inc., Johnson & Johnson, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, ... Read more (Read more...)
PRESS RELEASE: REGULATED INFORMATION Thursday, 16 November 2017, 07:00 CET BIOCARTIS Q3 2017 BUSINESS UPDATE Mechelen, Belgium , 16 November 2017 - Biocartis Group NV (the `Company` or `Biocartis`), ...
New CEO Joe Papa has done a nice job in his efforts to turn around Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Generic drugmakers have been taken to the woodshed, with Teva Pharmaceutical Industries Ltd (NYSE:TEVA) down 67% year-to-date and Mallinckrodt PLC (NYSE:MNK) off 56%.
Johnson & Johnson (JNJ) puts forth positive data from CANVAS study on its type II diabetes drug, Invokana, showing better renal outcomes.
Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is continuing the slow, painful process of unwinding from its debt and becoming a regular drug company.
Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.
CHMP has given a positive opinion recommending the marketing approval of Merck's (MRK) Prevymis for the prevention of CMV infection.
Merck , known as MSD outside the United States and Canada, announced today the final results of the previously announced offers to purchase any and all of the outstanding notes listed in the table below .